Cue Biopharma, Inc. (CUE): Results of Operations and Financial Condition
Cue Biopharma, Inc. (CUE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 cue-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights • Announced recent Investigational New Drug (IND) submission to the FDA for CUE-221 in food allergy applications • Completed a $50 mill
How this was made
The 30-second read
Why it matters
The filing combines (1) updated financials with large one-time non-cash and transaction-related items, (2) a new $50M private placement to fund development, and (3) a fresh FDA IND submission for CUE-221 plus stated expectations for upcoming clinical milestones.
Market read
Traders can update near-term expectations for CUE-221’s next clinical catalyst (Phase 2 readout timing) and reassess dilution/cash runway after the $50M PIPE.
What to watch
The balance sheet shows $17.4M cash at June 30, 2026 before the PIPE; traders may model runway and dilution impact using the PIPE size and the stated one-time cash outflows tied to the license agreement.
Background
This is an SEC 8-K (Item 2.02) with Q2 2026 financial results and business highlights for Cue Biopharma’s CUE-221 and CUE-401 programs.
Ticker impact
Cue Biopharma reported Q2 2026 results and disclosed a $50M PIPE, plus an FDA IND submission for CUE-221 in food allergy applications.
Choppy reaction risk: positive catalyst from IND submission and planned Phase 2 data timing, offset by dilution and large one-time non-cash charges.
The filing is a primary disclosure (8-K/Ex-99.1) with concrete financing ($50M PIPE) and clinical milestones (IND submission; Phase 2 data anticipated by end of Q3 2026). However, it does not provide new Phase 2 efficacy data, so direction depends on how investors weigh dilution and cash needs versus pipeline progress.
Market effects
Adds another clinical-stage biotech financing and IND milestone, but no clear sector-wide regulatory or competitive read-through is provided.
Primarily US small/mid-cap biotech sentiment; no specific regional macro linkage.
Limited global impact beyond potential collaboration economics (Boehringer Ingelheim) mentioned, without new deal terms.
Counterpoint
Investors may discount the IND submission as incremental versus the lack of new Phase 2 efficacy data, and focus on the magnitude of one-time charges and cash burn.
Key entities
- issuerCue Biopharma, Inc.
Clinical-stage biopharmaceutical company advancing CUE-221 (anti-IgE) and CUE-401 toward Phase 2/Phase 1 milestones.
- drug_programCUE-221
Anti-IgE antibody with a dual mechanism; IND submitted for food allergy applications; Phase 2 data anticipated by end of Q3 2026 in chronic spontaneous urticaria.
- counterpartyAscendant
Referenced in the license agreement that drove one-time non-cash warrant-related losses and related payments.
- collaboration_partnerBoehringer Ingelheim
Collaboration revenue recognized in Q2 2026 tied to a preclinical milestone.
